Vaccine

Arbor Biotechnologies Appoints Mikael Dolsten, M.D., Ph.D., to Board of Directors

Former Pfizer Chief Scientific Officer brings decades of drug development and strategic leadership experience to Arbor’s BoardCAMBRIDGE, Mass., June 25,…

6 months ago

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane,…

6 months ago

Dräger: New research should serve as a ‘wake up call’ for businesses to avoid ‘perfect storm’ for workplace health and safety

New research finds that while the broad majority (96%) of people feel safe at work, a sizeable 65% believe that…

6 months ago

Kicking Off Today! Process Intensified. Drug Manufacturing Accelerated. The Sartorius PI Forum opens in Boston — shaping biomanufacturing’s future

Sartorius launches a premier industry event focused on process intensification (PI) for protein therapeutics and emerging modalities.Forum features expert-led sessions,…

6 months ago

Label-free Detection Market to Accelerate Growth from USD 2.64 Billion to USD 4.48 Billion by 2032 – Meticulous Research®

Rising Pharmaceutical Innovation, AI Integration, and Point-of-Care Testing Applications Drive 9.8% CAGR Growth Across Healthcare and Biotechnology Sectors Worldwide REDDING,…

6 months ago

Risky urgent care provider behavior increased in 2025, Chatmeter analysis finds

Review of provider responses to online reviews also found up to 46% contained potential HIPAA violations SAN DIEGO, June 24,…

6 months ago

New Study Reveals 82% of Physicians Question Safety and Quality of Medical Products They Prescribe

Majority express concerns about medical research integrity due to political and commercial influences and over half report declining confidence in regulatory…

6 months ago

Serina Therapeutics to Present at FORCE Family Office Investor Webinar on June 26, 2025

How Parkinson’s affects million – and why current treatments are not enoughContinuous dopaminergic stimulation (CDS): a next-gen approach to Parkinson’s…

6 months ago

Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared…

6 months ago

Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid

Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid Approval based on pivotal…

6 months ago